Corporate Updates and Clinical Progress to be Highlighted
CORALVILLE, Iowa, Feb. 13, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the Company’s Chairman, President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the RBC Capital Markets 2018 Global Healthcare Conference being held February 21-22, 2018, at the Lotte New York Palace Hotel.
Details of KemPharm's presentations are as follows:
|Event:||RBC Capital Markets 2018 Global Healthcare Conference|
|Date:||Wednesday, February 21, 2018|
|Time:||4:05 PM (EST)|
|Location:||Lotte New York Palace Hotel, Holmes Room #2, New York, NY|
The presentation webcast will available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/ following delivery at the conference.
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) platform technology. KemPharm utilizes its proprietary LAT™ platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD. In addition, the company is advancing Apadaz™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen, as well as KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate. Both Apadaz™ and KP201/IR are designed to deter abuse and are intended for the treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Caution Concerning Forward Looking Statements:
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2016, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
|Investor Contacts:||Media Contact:|
|Jason Rando / Joshua Drumm, Ph.D.|
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
|Daniel L. Cohen|
Executive VP, Government and Public Relations